Tirzepatide or Retatrutide, an alternative, NOT a combination Tirzepatide and Retatrutide are competing multi-receptor molecules
24, 39, 40, 268, 269 A key issue for future clinical trial design will be to identify clinically relevant objective criteria for patient enrollment, and this remains a challenge, which has delayed a more aggressive approach of the pharmaceutical industry to identifying new treatment avenues for this condition
Funding Statement This work was supported by the University of Zagreb, Zagreb, Croatia (Grant BM 10106-22-3071)
Merck Millipore, Darmstadt, Germany), EDTA, ascorbic acid, S -()-propranolol, R -()-deprenyl hydrochloride, pargyline hydrochloride, clorgyline hydrochloride, yohimbine (Tocris, Bristol, United Kingdom), haloperidol, clozapine, olanzapine (Tocris), and [ 3 H]RX821002 (Perkin Elmer, Billerica, MA)